Outlook Therapeutics reports FY2024 net loss of $75.4M; LYTENAVA launch plans for H1 2025

Outlook Therapeutics, Inc.

Net loss of $75.4M ($4.06 per share) vs $59.0M ($4.72 per share) in prior fiscal year.
Cash and cash equivalents of $14.9M as of September 30, 2024.
LYTENAVA (bevacizumab gamma) approved in EU and UK for wet AMD; NICE recommends in UK.
NORSE EIGHT month 3 efficacy data expected January 2025; BLA resubmission targeted Q1 2025.
First commercial launches in UK and Germany planned H1 2025; potential US FDA approval H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.